For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240611:nRSK8834Ra&default-theme=true
RNS Number : 8834R MicroSalt PLC 11 June 2024
11 June 2024
MicroSalt Plc
("MicroSalt" or the "Company")
Exercise of Warrants, Exercise of Options and Total Voting Rights
MicroSalt plc, a company commercialising a patented technology to produce
full-flavour, low-sodium salt for food manufacturers and consumers, announces
that 3,453,500 ordinary shares of £0.001625 each ("Ordinary Shares") have
been allotted to certain shareholders to satisfy the exercise of warrants and
options in the Company.
Exercise of Warrants
Further to the announcement dated 24 May 2024, the Company has exercised its
right under the warrant instrument dated 26 January 2024 to call outstanding
warrants over 7,313,976 Ordinary Shares ("Warrants"), pursuant to which,
3,153,500 Warrants have been exercised by warrant holders. The Warrants are
exercisable at a price of 47.3 pence per Ordinary Share. Further details of
the Warrants are contained in the Company's Admission Document, available on
the Company's website www.microsalt.co (http://www.microsalt.co) .
Exercise of Options
Options over a total of 300,000 Ordinary Shares have been exercised under the
Group's 2022 share option plan (the "Plan"). Pursuant to the terms of the
Plan, the exercise price of each Option is US$0.25.
Application has been made to the London Stock Exchange for the admission of
3,453,500 new Ordinary Shares. It is expected that admission will become
effective on or around 14 June 2024 ("Admission").
Total Voting Rights
Following Admission, the total number of ordinary shares and voting rights in
the Company will be 46,670,654. The Company does not hold any shares in
treasury.
The above figure may be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please visit MicroSalt's website
(https://microsaltinc.com/home-uk/) or contact:
MicroSalt plc Via Flagstaff PR
Rick Guiney, CEO
Zeus (Nominated Adviser and Broker) +44 (0)20 3829 5000
David Foreman / James Edis (Investment Banking)
Dom King (Corporate Broking), Rupert Woolfenden (Sales)
Flagstaff PR (Financial PR/IR) +44 (0)20 7129 1474
Tim Thompson / Alison Allfrey / Anna Probert
Notes to Editors
MicroSalt® produces a patented full-flavour, low-sodium salt for food
manufacturers and consumers.
MicroSalt is a major potential disruptor in the food market, thanks to its
micron sized particles which deliver the same sense of saltiness to a wide
range of foods but with approximately 50% less sodium. Excess sodium
consumption is a significant contributor to cardiovascular disease and
MicroSalt's solution meets the rising demand for healthier alternatives to
traditional salt. The WHO has set a target for reducing global sodium intake
by 30% by 2025, which it estimates will save 7 million lives by 2030.
Each year, cardiovascular disease costs the UK £19 billion - if the average
salt intake was reduced by one gram per day, it has been estimated that 4,147
lives and £288 million would be saved each year in the UK. As a nation, the
UK consumes 183 million kilograms of salt each year, and 70 per cent. of the
typical person's sodium intake is hidden in processed foods.
Operational since 2018, MicroSalt uses a patent-protected technology which
helps create high barriers to entry within the reduced-sodium salt market. The
group has a US patent and 14 patent applications pending in other
jurisdictions globally.
The Directors believe that MicroSalt is well positioned to capture growth in
the low sodium market, which is expected to grow exponentially, and that there
is also scope to enter the larger salt market.
MicroSalt has a three-pronged marketing strategy, targeting large B2B food
manufacturers, the B2C market and e-commerce customers. MicroSalt's all
natural, low-sodium solution is well positioned to take advantage of the
fast-growing market for a healthier alternative to traditional salt.
ENDS
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEQKKBBBBKBFAD